Atomoxetine and Duloxetine: Evaluation of a Potential Pharmacokinetic Drug-Drug Interaction
References
- 1. Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm. 2004;61(22):2391–9.
- 2. Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child. 2005;90 Suppl 1:i26-9.
- 3. Sauer J-M, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44(6):571–90.
- 4. Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos. 2002 ;30(3):319–23.
- 5. Yu G, Li G-F, Markowitz JS. Atomoxetine: A review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016;26(4):314-26.
- 6. Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011;50(5):281–94.
- 7. Wernicke JF, Gahimer J, Yalcin I, Wulster-radcliffe M, Viktrup L. Safety and adverse event profile of duloxetine. Expert Opin Drug Saf. 2005;4(6):987-93.
- 8. Carter NJ, McCormack PL. Duloxetine: A review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523–41.
- 9. Sobanski E, Paslakis G, Schredl M et al. Managing ADHD in adults with common comorbidities. In: Surman C, ed. ADHD in adults. A practical guide to evaluation and managament. Current Clinical Psychiatry. Totowa, NJ: Humana Press; 2013. p. 137–54.
- 10. Bond DJ, Hadjipavlou G, Lam RW et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry. 2012;24(1):23–37.
- 11. Kooij JJS, Bijlenga D, Salerno L et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry. 2019;56:14–34.
- 12. Dodangi N, Habibi N, Astaneh AN. Preliminary investigation on duloxetine efficacy in the treatment of children with attention-deficit hyperactivity disorder. J Compr Pediatr. 2015; 6(4):e27482. doi: 10.17795/compreped-27482.
- 13. Niederhofer H. Duloxetine may improve some symptoms of attention-deficit/hyperactivity disorder. Prim Care Companion J Clin Psychiatry. 2010;12(2): PCC.09l00807. doi: 10.4088/PCC.09l00807pin.10.4088/PCC.09l00807pin
- 14. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–91.
- 15. Todor I, Popa A, Neag M et al. Evaluation of the potential pharmacokinetic interaction between atomoxetine and fluvoxamine in healthy volunteers. Pharmacology. 2017;99(1-2):84-88.
- 16. Todor I, Popa A, Neag M et al. Evaluation of a potential metabolism-mediated drug-drug interaction between atomoxetine and bupropion in healthy volunteers. J Pharm Pharm Sci. 2016;19(2):198–207.
- 17. Todor I, Popa A, Neag M et al. The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. Clujul Med. 2015;88(4):513-520.
- 18. Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet.2015;387(10024):1240–50.
- 19. Biederman J, Petty CR, Evans M, Small J, Faraone S V. How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD. Psychiatry Res. 2010;177(3):299–304.
- 20. Faraone S V, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159–65.
- 21. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012;9(3):490–9.
- 22. Fayyad J, De Graaf R, Kessler R et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402–9.
- 23. Wang B, Yang L-P, Zhang XZ, Huang SQ, Bartlam M, Zhou SF. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab Rev. 2009;41(4):573–643.
- 24. Lin ND, Norman H, Regev A et al. Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims database. BMC Gastroenterol. 2015; 15:134. doi: 10.1186/s12876-015-0373-4.10.1186/s12876-015-0373-4
- 25. Belle DJ, Ernest CS, Sauer J, Smith BP, Thomasson HR, Witcher JW. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol. 2002;42(11):1219-27.
- 26. Childress AC. A critical appraisal of atomoxetine in the management of ADHD. Ther Clin Risk Manag. 2015; 12:27-39.
- 27. Fredriksen M, Halmøy A, Faraone S V, Haavik J. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD : A review of controlled and naturalistic studies. Eur Neuropsychopharmacol. 2013;23(6):508-27.
- 28. Hennissen L, Bakker MJ, Banaschewski T et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD : a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs. 2017;31(3):199–215.
- 29. Kasi PM, Mounzer R, Gleeson GH. Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system. Case Rep Med. 2011;2011:952584. doi: 10.1155/2011/952584.
Language: English
Page range: 150 - 156
Submitted on: May 27, 2019
Accepted on: Jul 12, 2019
Published on: Dec 31, 2019
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2019 Ioana Todor, Adina Popa, Dana Muntean, Maria Neag, Ana-Maria Gheldiu, Corina Briciu, Daniel Leucuta, Laurian Vlase, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.